Understanding Autosomal Dominant Optic Atrophy

Introduction to Autosomal Dominant Optic Atrophy (ADOA)

• Autosomal dominant optic atrophy (ADOA) is a type of mitochondrial disease that affects the optic nerves, causing vision loss, and is often misdiagnosed as normal tension glaucoma 00:00
• The signs and symptoms of ADOA may first become noticeable in childhood, with children experiencing difficulty seeing the blackboard at school, or later in life, with vision loss being mild and sometimes not noticeable 08:47

Diagnosis and prognosis of ADOA

• Diagnosis of ADOA involves a range of tests, including visual acuity measurements, optical coherence tomography (OCT) scans, and genetic testing, particularly for the OPA1 gene, which is responsible for ADOA 07:46
• The prognosis of vision loss in patients with Autosomal Dominant Optic Atrophy (ADOA) is variable, with some patients losing one line on the vision chart every 5 years, but it’s rare to lose vision completely 12:05.
• Research has shown that about 60% of patients with ADOA have no change in vision over time, and the speed of vision loss does not seem to depend on the type of mutation in the OPA1 gene 13:31.

Clinical management and support for people with ADOA 
In the eye clinic, patients with ADOA are managed by ensuring there are no other eye problems, managing nutritional deficiencies, providing vision support, and looking after overall eye health 13:51.

Emerging therapies and clinical trials
New therapies are being developed to improve the production of healthy OPA1 in patients with ADOA, and some of these therapies are currently in phase one trials 14:45.
A trial called the Myrtle study is being conducted to test a new therapy for patients with ADOA, and it is looking for patients aged over 18 with confirmed OPA1 genetic changes 16:10.

Genetic basis and mechanisms of ADOA

• The OPA1 protein is encoded by the nucleus and forms ring-like structures in the mitochondria, and errors in the OPA1 gene can lead to ADOA 23:33.
  Patients with ADOA experience not only vision loss but also emotional challenges, such as anxiety and isolation, and practical challenges, such as uncertainty and worrying about the future 18:13.
• Healthcare teams are advised to take patients with ADOA seriously, learn about the condition, and be willing to learn, and to provide emotional support and recognize the impacts of ADOA beyond vision loss 19:14.
• Autosomal Dominant Optic Atrophy (ADOA) is caused by problems with the OPA1 gene, which affects the mitochondria and leads to vision loss due to high energy demands in cells connecting the eye to the brain via the optic nerve 25:21.
• The condition is passed down from a parent to a child about 50% of the time, and it can also arise spontaneously in some families, with a pattern of inheritance that follows autosomal dominance 26:20.

Impact on patients and healthcare provider guidance

• Patients with ADOA experience not only vision loss but also emotional challenges, such as anxiety and isolation, and practical challenges, such as uncertainty and worrying about the future 18:13.
• Healthcare teams are advised to take patients with ADOA seriously, learn about the condition, and be willing to learn, and to provide emotional support and recognize the impacts of ADOA beyond vision loss 19:14.

Genetic testing and family implications

• Genetic testing can provide diagnostic certainty, determine who else in the family might be at risk, and offer options like pre-implantation genetic diagnosis and in vitro fertilization for families like Kim’s, who live with ADOA 29:34.
• Autosomal dominant optic atrophy (ADOA) is a condition where some family members may be unaffected carriers of the OPA1 mutation, with 17% of people in the normal range actually carrying the mutation 38:18.

Long-term vision outcomes and research

• Research has shown that vision can change over time in people with ADOA, with some people’s vision improving, while others experience a decline, and the average time of follow-up was over 10 years 41:38.
• A new research project is underway in Australia to investigate why some family members with ADOA are severely affected while others are not, and to determine the factors that influence vision loss 44:41.

Support organisations and resources

• The Cure ADOA foundation and the ADOA association are two organisations committed to making progress in Autosomal Dominant Optic Atrophy (ADOA) and provide useful resources for those affected 50:28
• The Mito Foundation website is a valuable resource for learning about mitochondrial disease, with information available in multiple languages, and is particularly relevant for those in Australia 51:07
• The Mito Registry, maintained by the Mito Foundation, collects information to support clinical research and connect people with ADOA and other mitochondrial diseases, and is open for registration